ACUTE PROMYELOCYTIC LEUKEMIA

Transcription

1 With the partnership of 5 th INTERNATIONAL SYMPOSIUM ON ACUTE PROMYELOCYTIC LEUKEMIA Rome, Maintenance Congress Centre Grand Hotel Parco dei Principi, September 24-26, 2009 Chairmen: F. Lo Coco, M.A. Sanz Honorary President: F. Mandelli

2 5 th INTERNATIONAL SYMPOSIUM ON ACUTE PROMYELOCYTIC LEUKEMIA Rome, Maintenance Congress Centre Grand Hotel Parco dei Principi, September 24-26, 2009 Dear Colleague, FACULTY we are pleased to invite you to the Fifth International Symposium on Acute Promyelocytic Leukemia that will be held in Rome on September 24th 26th, The symposium has traditionally been organised every four years since 1993 when it was first established by Professor Franco Mandelli. Most leading experts working on either basic or clinical aspects related to this leukemia are come together in this meeting where they have a unique opportunity to present their work and share scientific information. APL is a model for unravelling key mechanisms of leukemogenesis and is a paradigm for innovative treatments including differentiating and anti-apoptotic agents, targeted immunotherapy, and chromatin remodelling agents. In fact, this disease is today one of the most successful examples of translational research in medicine. Over the past two decades, APL has evolved from being the most rapidly fatal to the most frequently curable acute leukemia. These improvements relate to developed countries where highly specialised diagnosis and clinical care are available. However, difficulties in accessing adequate infrastructures and insufficient networking at the national level has prevented the achievement of similar results in less privileged regions. Moreover, in spite of the striking progress in our understanding of APL pathogenesis, the causes of the disease are still unknown. Clearly, there is still much room for implementation, debate and, particularly, cooperation at both the national and international level. This symposium will offer to researchers and clinicians a unique forum for debate and collaboration. We look forward to seeing you in the Eternal City. Myriam Alcalay Sergio Amadori Giuseppe Avvisati Nancy Berliner (USA) Alan K. Burnett (UK) Mammen Chandy (India) Sai-Juan Chen (China) Christine Chomienne (France) Hugues de Thé (France) Laurent Degos (France) Elihu Estey (USA) Anna Falanga Pierre Fenaux (France) Robert Gallagher (USA) Francesco Grignani David Grimwade (UK) Florence Guibal Richard A. Larson Eva Lengfelder Giuseppe Leone Jonathan Licht Francesco Lo Coco Bob Löwenberg Lucio Luzzatto Franco Mandelli Vikram Mathews Wilson H. Miller Saverio Minucci Tomoki Naoe Clara Nervi Neil Osheroff Fabrizio Pane (France) (USA) (Germany) (USA) (NL) (India) (Canada) (Japan) (USA) Pier Giuseppe Pelicci Bayard L. Powell (USA) Eduardo Rego (Brazil) Gail J. Roboz (USA) Martin Ruthardt (Germany) Giuseppe Saglio Valeria Santini Miguel A. Sanz (Spain) Josè I. Martin Subero (Spain) Martin S. Tallman (USA) Christian Thiede (Germany) Sante Tura Arthur Zelent (UK) Jiang Zhu (China) With best personal regards, Francesco Lo Coco Symposium co-chairman Miguel A. Sanz Symposium co-chairman

3 1.30 pm Registration desk opens pm EDUCATIONAL SESSION (repeated on Friday in Spanish) Diagnostics & minimal residual disease F. Lo Coco Front-line therapy M.A. Sanz Treatment of relapse P. Fenaux pm NOVARTIS ONCOLOGY SYMPOSIUM Targeted therapy in acute myeloid leukemia Chairman: B. Löwenberg Role of genetic lesions in APL and AML C. Thiede Clinical application of targeted therapies for AML R. Larson Discussion pm Coffee break and posters viewing pm CELGENE SYMPOSIUM Molecular pathways and therapeutic intervention in myelodysplasia and acute myeloid leukemia Chairmen: F. Pane, S. Tura Molecular pathogenesis G. Saglio Clinical activity of Lenalidomide in MDS/AML P. Fenaux Clinical activity of Azacitidine in MDS/AML V. Santini pm OPENING CEREMONY pm OPENING LECTURE Recent insights into APL pathogenesis and treatment H. de Thé 7.30 pm Welcome Cocktail THURSDAY, SEPTEMBER 24 THURSDAY, SEPTEMBER 24

4 am PLENARY SESSION I - Leukemic stem cell Chairmen: M. Alcalay, J. Licht Identification of a myeloid committed progenitor as the cancer initiating cell in acute promyelocytic leukemia F. Guibal Partially-differentiated but not mature APL cells retain the potential to reinitiate an original type of leukemia J. Zhu Regulation of self-renewal in leukemic stem cells P.G. Pelicci Targeting the PML/RAR-positive stem cells M. Ruthardt am Coffee break and posters viewing pm PLENARY SESSION II - Signaling pathways Chairmen: F. Grignani, P.G. Pelicci Gene networks regulated by PLZF and PLZF- RARα J. Licht pm Lunch Retinoic acid signaling and differentiation of APL and non-apl AML A. Zelent Highlights of retinoic acid functions in APL and other leukemias C. Chomienne Mechanisms and therapeutic potential of arsenicals: APL and beyond W.H. Miller pm PLENARY SESSION II - Management of APL in developing countries Chairmen: N. Berliner, B. Löwenberg An international consortium on APL: why? B. Löwenberg Results of the IC-APL project in Brazil E. Rego Socio-economic, logistic and organizational issues of APL treatment in India M. Chandy FRIDAY, SEPTEMBER 25 FRIDAY, SEPTEMBER 25

5 pm pm SIMULTANEOUS SESSIONS FERNANDES ROOM Molecular biology Chairmen: R. Gallagher, S. Minucci PALLAVICINI-MEDICI ROOM Front-line management of APL and special situations (Children, elderly, developing countries) Chairmen: G. Avvisati, E. Estey FERNANDES ROOM Prognostic factors and therapy of APL relapse Chairmen: G. Saglio, M.S. Tallman PALLAVICINI-MEDICI ROOM Supportive care and coagulopathy Chairmen: A. Falanga, M.A. Sanz pm EDUCATIONAL SESSION (Spanish version) am PLENARY SESSION IV - Epigenetics and transcription targeting Chairmen: L. Luzzatto, C. Nervi Epigenomic profiling of hematological neoplasms J.I. Martin Subero Evaluation of mechanisms of resistance to arsenic trioxide in acute promyelocytic leukemia V. Mathews Oncoproteins, epigenetic deregulation and micrornas: a new link for leukemogenesis C. Nervi am PLENARY SESSION V - Clinical trials update (I) Chairmen: L. Degos, F. Mandelli Gimema results using AIDA protocols G. Avvisati Exclusion of Ara-C does not reduce molecular response or cure rate in APL: experience from the MRC AML15 Trial A. Burnett FRIDAY, SEPTEMBER 25 SATURDAY, SEPTEMBER 26

6 Management of APL with single agent arsenic trioxide M. Chandy An update of clinical trials of the French Belgian Swiss APL group P. Fenaux Long term results of the German AML Cooperative Group in newly diagnosed APL E. Lengfelder am Coffee break and posters viewing pm PLENARY SESSION V - Clinical trials update (II) Cure of APL without chemotherapy: possibilities and importance E. Estey Arsenic trioxide consolidation therapy for adults with APL: North American Leukemia Intergroup Protocol C9710 B.L. Powell Current clinical trial of the Japan Adult Leukemia Study Group (JALSG) for newly diagnosed APL T. Naoe Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide based therapy in newly diagnosed APL S.J. Chen PETHEMA risk-adapted protocols: an update M.A. Sanz pm CEPHALON LUNCH SYMPOSIUM Arsenic trioxide in APL and beyond Chairmen: S. Amadori, A.K. Burnett Introduction Uncovering the innovative mechanism of action of arsenic trioxide W.H. Miller Curative strategies in the management of APL M.S. Tallman Use of arsenic trioxide in non-apl myeloid malignancies G. Roboz Panel Discussion SATURDAY, SEPTEMBER 26 SATURDAY, SEPTEMBER 26

7 pm PLENARY SESSION VI - Secondary APL Chairmen: D. Grimwade, G. Leone Molecular mechanisms in therapy-related APL D. Grimwade Topoisomerase II and Cancer: cure and cause N. Osheroff When APL occurs as a therapy-related myeloid neoplasm R. Larson 3.45 pm Closing remarks F. Lo Coco, M.A. Sanz 5 th INTERNATIONAL SYMPOSIUM ON ACUTE PROMYELOCYTIC LEUKEMIA Rome, Maintenance Congress Centre Grand Hotel Parco dei Principi, September 24-26, 2009 SATURDAY, SEPTEMBER 26

8 GENERAL INFORMATION MEETING VENUE Grand Hotel Parco dei Principi Via G. Frescobaldi, Rome Phone Fax LANGUAGE The meeting will be in English with no simultaneous translation. The educational session will be repeated in Spanish. CME The Italian Ministry of Health allows: 15 CME credits for physicians; 13 CME credits for biologists; 13 CME credits for technicians. The European Hematology Association allows 16 CME EHA credits. BADGE All registered participants, speakers and exhibitors will be given a badge which they must wear to be admitted to the scientific sessions. ATTENDANCE CERTIFICATE A certificate will be given to all participants at the end of the meeting. SLIDES Slides must be in English. Computer videoprojection will be available in Power Point. Other requirements should be communicated to the Organizing Secretariat as soon as possible. Slides should be handed to the slide center one hour before the beginning of the session and collected at the end. CHANGES Parts of the program may be changed if necessary. REGISTRATION FEES (In Euro - VAT included) Euro 450,00 Euro 250,00 under 30 years old Euro 200,00 accepted abstracts' submitters The registration fee includes: - Conference kit - Participation in the scientific sessions - Attendance Certificate - Welcome Cocktail - Coffee breaks - Lunches HOTEL REGISTRATION TRIUMPH VIAGGI & INCENTIVE S.R.L. - GRUPPO TRIUMPH Via Lucilio, Rome - Italy Phone Fax booking@gruppotriumph.it

9 SCIENTIFIC SECRETARIAT Claudia Carissimo Serena Lavorgna Syed K. Hasan Andrea Manfredonia Nelida I. Noguera ORGANIZING SECRETARIAT STUDIO E.R. CONGRESSI - GRUPPO TRIUMPH Via Marconi, Bologna, Italy Phone Fax ercongressi@gruppotriumph.it